CXCL8 and Alzheimer disease: With sufficient data from the most cohort studies among all the chemokines tested, there was no difference in CSF concentration of IL-8 (CXCL8) between AD patients and controls (average ratio 1.22, 95% CI, 0.99–1.50, corrected p = 0.174; I2 = 86.8%).